TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females, aged \>= 18 years at time of consent.~* Have a diagnosis of Psoriatic arthritis (PsA) of \>= 6 months~* Meet the Classification Criteria of PsA (CASPAR) at time of screening~* Must not have been adequately treated with a a traditional non-biologic disease modifying anti-rheumatic drug (DMARD).~* Concurrent treatment with methotrexate, leflunomide, or sulfasalazine allowed and required~* Must not have taken a biologic Tumour Necrosis Factor Inhibitor~* Must have 3 or more swollen joints AND 3 or more tender joints~* Must have active psoriasis skin lesions~Exclusion Criteria:~* Have non-plaque forms of psoriasis, eg erythrodermic, guttate or pustular, with the exception of nail psoriasis which is allowed~* Pregnant or breast feeding, females of child-bearing potential not using highly effective contraception~* New York Heart Association Class III and IV congestive heart failure~* History of hypersensitivity or infusion reaction to biologic agents~* Infection with HIV, hepatitis B virus, hepatitis C virus, or other chronic infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tofacitinib 5 mgBID x 12 months (Type: EXPERIMENTAL): None
- Tofacitinib 10 mg BID x 12 months (Type: EXPERIMENTAL): None
- Adalimumab 40 mg q2 weeks x 12 months (Type: ACTIVE_COMPARATOR): None
- Placebo x3 months, then tofacitinib 5 mg BIDx 9 months (Type: PLACEBO_COMPARATOR): None
- Placebo x 3 months, then tofacitinib 10 mg BID x 9 months (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CD20 positive lymphoma~* negative for HBsAg and positive for anti-HBc~* age over 16 years old~* alanine aminotransferase less than 2 times the upper limit of normal~* bilirubin \< 2.5 mg/dL~* neutrophil \> 2000/mm3~* platelet \> 100,000/mm3~* creatinine \< 1.5 mg/dL~* urea nitrogen \< 25 mg/dL~* Eastern Cooperative Oncology Group performance score 0 to 2~Exclusion Criteria:~* Child-Pugh class B or C cirrhosis~* grade 2 or greater heart failure by the NYHA classification~* previous chemotherapy,radiotherapy, or concurrent glucocorticoid therapy for other reasons~* other primary liver diseases, such as chronic hepatitis C, hepatitis D, autoimmune hepatitis, or Wilsons' disease

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Entecavir prophylaxis (Type: EXPERIMENTAL): Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of chemotherapy, and will be continued until 3 months after completion of the chemotherapy.
- Therapeutic arm (Type: ACTIVE_COMPARATOR): In patients with HBV reactivation and ALT flare \> 100 U/L, entecavir 0.5mg daily will be prescribed for the cases till hepatitis remission

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children, males and females, healthy or at high risk of complications from influenza, between ≥6 months to \<72 months of age~* Documented consent provided by the subject's parent(s)/legal guardian(s)~* Subjects and/or subject's parent(s)/legal guardian(s) able to comply with all study procedures.~Exclusion Criteria:~* Children with history of allergy to vaccine components.~* Additional eligibility criteria may be discussed by contacting the site

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 71 Months
- Healthy Volunteers: t

Study Arms:
- aQIV (Type: EXPERIMENTAL): flu vaccine
- non-adjuvanted comparator (Type: ACTIVE_COMPARATOR): flu vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy child without chronic severe disease of either gender,~2. 6 year-old child on vaccination day,~3. Child previously vaccinated with three doses of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination within the first 6 months of life and a booster dose of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination at 16 - 18 months of life (±2 months),~4. Consent form signed by both parents, or by the legal representative, properly informed about the study.~Exclusion Criteria:~1. Child who had received less or more than 4 doses of a diphtheria, tetanus and/or poliomyelitis containing vaccine,~2. Previous clinical or bacteriological diagnosis of diphtheria, tetanus or poliomyelitis,~3. Child who had received any vaccine in the previous 30 days or with a vaccination scheduled during the course of the study,~4. Child who present with immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity,~5. Child who had received within the previous 150 days or who will receive during the course of the study, any immunoglobulins or blood derived products,~6. Child with true hypersensitivity to at least one of the components of a study vaccine or to streptomycin, neomycin or polymixin B,~7. Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition,~8. Child who had presented severe hypersensitivity following an earlier immunization against diphtheria and/or tetanus,~9. Known history of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection,~10. Acute severe febrile illness and/or oral temperature ≥37.5°C at the time of vaccination

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Strategies for Teaching Verbs

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must use oral communication as their primary means of communication~* Must be monolingual English speakers~* Behaviorally able to attend for 20 minutes~* Children with typical development must demonstrate no more than one standard deviation below the mean on the speech and language measures~Exclusion Criteria:~* Nonverbal cognitive score less than three standard deviations below the mean (standard score of 54 below)~* Identified hearing loss or failed hearing screening~* Uncorrected vision impairment~* Motor impairment that prevents completion of study activities~* Concomitant disorders (e.g., Autism spectrum disorder)

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Verb strategies (Type: EXPERIMENTAL): The examiner labels each target word and performs the corresponding action six times in each condition. She elicits the target word from the participant two times per word per condition and provides feedback on accuracy each time. In the semantic cues condition, the examiner prompts the child to perform the target action twice. In the syntactic cues condition, instead of only saying the target word with the present progressive verb marker, the examiner uses two forms of complete sentences while performing the action (i.e., I am X-ing, and See. I X.). In the combined condition, the examiner prompts the child to perform the target action and consistently uses complete sentences.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Total Hip Replacement: The E-TRANS Fentanyl Transdermal System Versus the Morphine Intravenous Pump

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a pre-operative American Society of Anesthesiology Physical Status I, II, or III (Class I are healthy persons less than 80 years of age, Class II are patients over age 80 years of age with mild systemic disease, and Class III are patients with severe and non-incapacitating disease)~* Admitted to the Post-Anesthesia Care Unit after general or spinal anesthesia (using bupivacaine)~* Surgical time of up to 4 hours for total hip replacement surgery with a single surgical incision~* Awake and breathing spontaneously, with a respiratory rate of 8 to 24 breaths per minute and oxygen saturation of 90% or higher (with or without supplemental oxygen)~* Expected to remain hospitalized for at least 24 hours postoperatively~Exclusion Criteria:~* Patients whose post-operative pain would normally be managed with oral or non-narcotic pain medication~* Who received intraoperative spinal anesthesia other than bupivacaine (without epinephrine), intraoperative epidural anesthesia, or who are expected to have postoperative analgesia supplied by a continuous regional technique~* Have a history of allergy, hypersensitivity, or tolerance to fentanyl or morphine, or a history of allergy or hypersensitivity to cetylpyridinium chloride or skin adhesives, or have the presence of active skin disease that would interfere with application of the E-TRANS fentanyl system~* Who received systemic or intra-articular steroids within 1 month before surgery or during surgery~* Expected to require intensive care postoperatively or who will probably need additional surgical procedures within 72 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use contraception~* Willing to provide written informed consent and to comply with study requirements~* Normal electrocardiogram (ECG) at screening~* Hypertriglyceridemic patients must have a history of fasting serum triglycerides of at least 300 mg/dL (3.38 mmol/L) at screening or verifiable diagnosis of FCS~Exclusion Criteria:~* Clinically significant health concerns~* Regular use of alcohol within one month prior to Screening~* Use of an investigational agent or device within 30 days prior to dosing or current participation in an investigational study~* Recent use of illicit drugs~* Use of more than two tobacco/nicotine containing or cannabis products per month within 6 months prior to drug administration (applicable only to Normal Healthy Volunteers)~Note: additional inclusion/exclusion criteria may apply, per protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- ARO-APOC3 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years at the time of dalbavancin treatment initiation~* Male and female patients~* Patients who received dalbavancin as targeted or empirical therapy to treat Gram-positive bacterial infection or as anti-Gram-positive component of a treatment regimen for mixed infection (e.g., with concurrent antibacterial or antifungals drugs for covering Gram-negative strains or fungi)~* Patients who received the last dose of dalbavancin according to the current standard clinical practice at least 30 (+7) days before enrolment in the study~* Patients with known type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) at the time of infectious disease of interest diagnosis~* Patients with available retrospective data in medical charts, including information about dalbavancin treatment and diabetes history~* Patients who gave informed consent and personal data processing consent to take part into the study following local regulation.~Exclusion Criteria:~* Patients enrolled in a clinical trial in which treatment with dalbavancin was managed through a study protocol~* Patients diagnosed with any hyperglycemic state other than T1DM or T2DM at the time of dalbavancin treatment initiation~* Patients with long-term infection (over than 12 months of duration) at the time of dalbavancin treatment initiation~* Previous participation in this study. Participation is defined as having given informed consent in this study~* Pregnant or breast-feeding patients from start time of dalbavancin treatment initiation till enrolment visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion:~* Physician documented diagnosis of asthma which has been present for at least 6 months.~* Receiving a total daily dose of 200-500mcg/day beclomethasone dipropionate or equivalent for at least 4 weeks prior to the start of the run-in period.~Exclusion:~* Has had 3 or more courses of oral corticosteroids in the 12 months previous to visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Diuretic Response in Advanced Heart Failure: Bolus Intermittent vs Continuous INfusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced heart failure~* WET ≥ 12~* Systolic blood pressure ≤ 110 mmHg~* Serum sodium ≤ 135 mEq/L~* Left systolic ventricular insufficiency (FE \< 35%) note for at least 6 months~* Class NYHA III-IV despite medical treatment maximal~Exclusion Criteria:~* Acute coronary syndrome~* Shock cardiogenic~* Chronic renal failure stage V

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous infusion of loop diuretics (Type: ACTIVE_COMPARATOR): Furosemide continuous infusion: 125 or 250 mg die
- Intermittent infusion of loop diuretics (Type: ACTIVE_COMPARATOR): Furosemide bolus intermittent: 125 or 250 mg die

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects Of Native Collagen Type 2 Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:Patients aged 45-70 years with the diagnosis of primary knee OA according to the American College of Rheumatology (ACR) criteria, Kellgren Lawrence radiological stage II or III and knee pain -~Exclusion Criteria:Patients with intraarticular injections or physical therapy within the last year, a previous lower extremity surgery, oral treatment with glucosamine chondroitin or other natural health products within the last month, serious concomitant systemic diseases, peripheral or central neurological disorder, hypersensitivity to paracetamol or se¬vere cardiac, renal, hepatic, hematologic disease~-

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- paracetamol (Type: ACTIVE_COMPARATOR): The 1st group includes 19 patients given 1500mg/day paracetamol for three months
- native collagen type 2 + paracetamol (Type: EXPERIMENTAL): The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Healthy Volunteers: PARTS A, B, and C~* Males and Females of non-childbearing potential.~* Between the ages of 18 and 60 years inclusive~* Healthy, as defined per protocol.~* Body mass index (BMI) of 18.0 to 32.0 kg/m2 inclusive~* Body weight \>50 kg~CF Patients: PART D~* Body weight ≥35 kg.~* Males and Females of non-childbearing potential.~* Sweat chloride value ≥ 60 mmol/L at screening.~* Heterozygous for F508del and a minimal function CFTR mutation~* Forced expiratory volume in 1 second (FEV1) ≥40% and ≤90% of predicted at screening~Exclusion Criteria:~Healthy Volunteers: PARTS A, B, and C~* History of any illness or any clinical condition that in the opinion of the investigator might confound the results of the study or pose additional risk to the subject.~* Any condition possibly affecting drug absorption.~* History of febrile illness within 14 days before the first study drug dose.~* Glucose-6-phosphate dehydrogenase (G6PD) deficiency assessed at Screening.~CF Patients: PART D~* History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the subject.~* History of cirrhosis with portal hypertension.~* Risk factors for Torsade de Pointes.~* G6PD deficiency assessed at Screening.~* Abnormal Laboratory Values.~* Lung infection with organisms associated with a more rapid decline in pulmonary status~* History of solid organ or hematological transplantation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Part A: VX-659 or Matching Placebo (Type: EXPERIMENTAL): Part A includes single-dose escalation.
- Part B: VX-659 or Matching Placebo (Type: EXPERIMENTAL): Part B includes multiple-dose escalation.
- Part C: VX-659 in TC with TEZ/IVA or Matching Triple Placebo (Type: EXPERIMENTAL): Part C includes multiple dose escalation of VX-659 administered in Triple Combination (TC).
- Part D: VX-659 in TC with TEZ/IVA or Matching Triple Placebo (Type: EXPERIMENTAL): Part D includes subjects with CF. Participants will receive TC or matching placebos.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient meets DSM-IV criteria for Schizophrenia~* 18-60 years of age or older~* Able to give informed consent~* Treated with olanzapine, quetiapine, risperidone or ziprasidone for greater than or equal to 3 months prior to enrollment~Exclusion Criteria:~* pregnant or breastfeeding women will be excluded~* Meets DSM-IV criteria for substance abuse or dependence within past 6 months~* involuntary legal status (as per Missouri law)~* any serious medical disorder that may confound assessment of symptoms~* subjects taking prescription medications except psychotropic meds~* meets DSM-IV criteria for Mental Retardation (mild or worse)~* Subjects taking tricyclic antidepressants or mood stabilizers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Stayers (Type: OTHER): Subjects are randomized to stay on their current antipsychotic.
- Switchers (Type: OTHER): Subjects are randomized to switch to aripiprazole from their current antipsychotic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete